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 Shortly after Columbus had arrived in the New World, as the fifteenth century 
drew to a close, a terrible new disease which we now call syphilis appeared in Europe.  A 
controversy developed over whether or not the disease had been imported to Europe from 
the Americas, beginning with Columbus and his crew, or had existed in Europe earlier, 
perhaps in a different form.  The question of the origin of syphilis is still not firmly 
resolved today, but at present the evidence seems to be pointing against the American 
origin theory.  The venereal nature of syphilis was recognized relatively early. 
 Once the venereal nature of syphilis was understood, people could be (and were) 
warned against having intimate relations with individuals who were infected, assuming 
they could identify the infected.  But once one had contracted the disease, what remedies 
were available to alleviate, if not cure, the malady?    Some of those who believed that the 
pox was the just rewards of immoral behavior questioned whether or not those afflicted 
with the disease even deserved to be treated.1   
 Not surprisingly, when this terrible new disease first appeared, all sorts of 
remedies were recommended for dealing with it.  For example, Torella advised such 
strange treatments as applying a cock or pigeon flayed alive, or a live frog cut in two, to 
an infected penis.2   A major aim of most treatment was to remove the morbid matter 
causing the disease from the patient.  This could be done in various ways, for example, by 
blood-letting or the use of laxatives.  An alternative method involved having the patient 
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bathe in a mixture of wine and herbs, or in olive oil.  Syphilitics could also be placed in 
an enclosed heated space, causing them to sweat, another mechanism for eliminating 
corrupt matter from the body.3  
 The two remedies that eventually came to be by far the most popular, however, 
were mercury and guaiacum.  Mercury had long been used, especially by the Arabs, in 
the treatment of skin diseases and even leprosy.  Therefore it seemed reasonable to try it 
against syphilis, which generally involved skin lesions and was thought to resemble 
leprosy.  Numerous physicians in the early sixteenth century advocated the use of 
mercury in the forms of ointments or rubs.  Even anti-venereal underpants, coated on the 
inside with a mercurial ointment, were available in Italy.  It was recognized, however, 
that excess mercury could be harmful.  Overdosing with mercury could lead to such toxic 
side effects as shaking, paralysis, and the loosening and loss of teeth.  Sometimes the 
mercury was applied to the body and the patient was then placed in a heated area for long 
periods of time.  This introduced the possibility of mercury vapors entering the 
respiratory tract, which could be very dangerous.4 
 At first mercury was only given externally, for example, in the form of an 
ointment.  The internal administration of mercury seemed to be too dangerous.  At the 
end of the eighteenth century, however, the internal administration of mercury began to 
overtake the external methods.  The mercury could be administered in the form of 
enemas, or taken orally in a gum form or as calomel (the salt mercurous chloride).  Van 
Swieten’s liquor, consisting of grains of corrosive sublimate (mercuric chloride) 
dissolved in a solution of water and alcohol, became popular in the late eighteenth 
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century.  Mercury poisoning was probably not uncommon, but side effects that were 
probably due to the treatment were often attributed to the disease itself.  Mercury 
remained the preferred treatment for syphilis up into the twentieth century.5 
 The principal challenger to mercury in the early history of syphilis was guaiacum 
(or guaiac) wood.  The guaiacum tree was native to the Indies, and the Spanish and the 
Portuguese began using the wood to treat syphilis by the early fifteenth century.   At the 
time, it was widely believed that God often placed remedies for a disease in the areas 
where that disease flourished.  Since many Europeans began to ascribe the origins of 
syphilis to the Americas, it did not seem unreasonable that a cure for the disease might 
exist in that part of the world.6 
 The wood was administered by grinding it into a powder and then boiling it in 
water.  The resulting decoction (the liquid remaining when the wood is removed) was 
then ingested by the patient.  But typically treatment with guaiacum involved much more 
than simply drinking a decoction made from the wood.  The patient was generally placed 
in a warm room and put on a strict diet with limited food intake.  He or she was also 
given mild laxatives.  The patient then drank a large dose of the decoction daily, after 
which he or she was wrapped in blankets to induce sweating.  This regimen was carried 
out for thirty days, and was undoubtedly quite debilitating to the patient.  A 1519 book by 
the German humanist and religious reformer Ulrich von Hutten on guaiacum, which was 
translated into several languages, helped to popularize the drug.  Hutten himself suffered 
from syphilis and was convinced that he had been cured by guaiacum (although he 
appears to have eventually died of syphilis).  As s
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medical establishment, he was delighted to recommend an empirical remedy that came 
from a “barbarian” land with no doctors.7   
 Historian Sheldon Watts has suggested that the Spaniard Oviedo, whom we have 
already encountered as the first person to ascribe the origins of syphilis to the New 
World, helped to popularize guaiacum for financial reasons.  While in the Indies, Oviedo 
learned that the wood was a reputed cure for syphilis.  According to Watts, Oviedo knew 
that the public accepted the doctrine that for every disease or poison God had placed a 
cure nearby, and so he claimed that the people of the Indies had long suffered from 
syphilis but were able to cure the disease with guaiacum.  He arranged for his partners, 
the Fugger family of bankers, to obtain monopoly rights from the King of Spain to import 
and market the wood throughout the Spanish Empire.  This arrangement resulted in 
handsome profits for Oviedo and the Fuggers.8  
 Mercury and guaiacum were also not infrequently used together in the treatment 
of syphilitics by doctors anxious to cover all bases.   In the sixteenth century, the efficacy 
of guaiacum was challenged by Paracelsus, and its use began to progressively decline.  
Sometimes it was replaced by other woods and roots, included sarsaparilla, another 
American import.  Mercury temporarily lost some of its credibility around the beginning 
of the nineteenth century, but made a comeback by the 1860s.  Although there were 
certain new treatments that were employed in the nineteenth century, such as potassium 
iodide and certain preparations of arsenic, Quétel has concluded that other forms of 
treatment had a hard time competing with mercury.  Mercury remained king in the 
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treatment of syphilis until the twentieth century, although it left much to be desired as a 
remedy.9 
 While Mercury continued to dominate the treatment of syphilis, and, in 
desperation, physicians tried a host of other methods as well.  The chancres or ulcers of 
syphilis victims were sometimes cauterized (burned with a heated instrument or caustic 
substance).  Steam baths were combined with mercury vapor.  One doctor even tried 
using smallpox vaccination as a treatment for syphilis.  Thomas Lowry wrote about the 
case of one poor soldier in the Union Army during the American Civil War in the 1860s 
as follows: 
“Surgeon E. A. Tomkins of Fort Yamhill, Oregon, described an 
unfortunate soldier with syphilis who, over a period of about four month, 
was treated with potassium iodide in sarsaparilla, corrosive sublimate, 
lunar caustic, calomel, black draught, emetics, blistering, iron, quinine, 
and external chloroform.  At the end of the treatment, he was in severe 
pain, with one leg badly swollen and cold, barely able to walk.”10 
 In the early years of the twentieth century the cause of syphilis was uncovered and 
a diagnostic test for its detection became available.  Soon another major advance 
occurred that was to transform the treatment of the disease.   Paul Ehrlich, who had been 
devoting much of his research in the 1890s to immunology, returned in the first decade of 
the twentieth century to a subject that had interested him earlier, the development of 
chemical agents to treat infectious disease.  Ehrlich and his coworkers in Frankfurt began 
a search for chemical substances that would attack disease-causing microorganisms 
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within the body.  The hope was to find chemical drugs that acted like “magic bullets” that 
would specifically destroy the microorganisms without injury to human cells.  His work 
initially focused on a group of microorganism called trypanosomes, which caused such 
diseases as sleeping sickness. 
 Ehrlich learned in 1905 that two British researchers had found that the arsenic-
containing organic compound atoxyl could eliminate trypanosomes from the blood of 
infected animals.  Unfortunately, it was soon found that relapses commonly occurred and 
that that the large therapeutic doses required could damage the optic nerve and produce 
blindness.  Ehrlich reasoned, however, that he might be able to modify the structure of 
atoxyl in a way that reduced or eliminated its effect on the optic nerve while still 
retaining its toxicity towards trypanosomes.  Over the next few years, hundreds of arsenic 
compounds were synthesized and tested in his laboratory. 
 After the discovery of the spirochete that caused syphilis in 1905, Ehrlich began 
trying arsenical drugs against syphilis as well because there appeared to be a similarity 
between trypanosomes and spirochetes.  In 1909, the Japanese scientist Sahachiro Hata, 
working in Ehrlich’s laboratory, discovered that compound number 606 was effective in 
treating syphilis infections in rabbits.  After extensive animal tests, Ehrlich arranged for 
the drug to be distributed to selected medical specialists for human clinical trials.  The 
results were promising, and in 1910 Ehrlich announced the new drug to the world.   
Demand for 606 soon outgrew the ability of Ehrlich’s laboratory to produce it, and he 
arranged with a German chemical company to produce the drug under the tradename 
Salvarsan.11 
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 Salvarsan represented the first effective treatment for syphilis, and hence was 
hailed as a major medical breakthrough.  Although the drug was indeed a major advance 
in the treatment of the disease, it was by no means an ideal therapeutic agent.  Salvarsan, 
as an arsenical compound, had serious side effects.  It also had to be administered by 
injection, and treatment was prolonged, sometimes involving an injection a week for a 
year or more.  Ehrlich did introduce a somewhat improved form of the drug, 
Neosalvarsan, within a few years, and other arsenicals were introduced later.  In spite of 
the problems with arsenical therapy, it remained the primary form of treatment of syphilis 
from its introduction until the discovery of the effectiveness of penicillin against the 
disease in the 1940s. 
 Initially the length of treatment with arsenical drugs generally extended from 
several weeks to perhaps two months.  Treatment regimens varied, however, and the high 
cost of the drug meant that there was a tendency to stop its use once the Wasserman test, 
measuring the presence in the blood of the spirochete that caused syphilis, was negative.  
As a result of experience during the First World War and immediately thereafter, 
however, it became clear that it was necessary to continue treatment for a significantly 
longer period of time in order to avoid relapse.   
 In 1921, the use of bismuth to enhance the efficacy of the arsenicals was 
introduced.  Like arsenic and mercury, however, bismuth had certain toxic side effects.  
During the 1920s, the standard therapy for syphilis involved weekly injections of arsenic 
preparations, frequently rotated with mercury and bismuth compounds, for a period of 
one to two years.  In the United States, the most widely accepted schedule was that 
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developed by the Cooperative Clinical Group, organized in 1928 by five large American 
syphilis clinics.  Their protocol for acute syphilis involved weekly injections of 
Neosalvarsan and bismuth, on an alternating schedule, for a period of 68 weeks.  This 
regimen was complicated to administer, expensive, prolonged, and potentially dangerous, 
and patients did not always complete the full course of therapy.12  
 Although this therapy was reasonably effective in the treatment of primary and 
secondary syphilis, side effects ranged from relatively minor ones, such as nausea and 
headache, to serious problems such as necrosis (death of skin cells) at the site of 
injection, kidney failure, and acute hepatitis, occasionally resulting in death.  In addition, 
arsenical therapy had little or no effect in cases of advanced neurosyphilis, a late stage of 
the disease affecting the nervous system.  This was especially true in patients who had 
developed general paresis, involving brain damage and characterized by dementia and 
paralysis.13   
 In 1917, however, an Austrian physician began experimenting with a form of 
therapy for paresis that became widespread in the 1920s and after.   A medical graduate 
of the University of Vienna, Julius Wagner-Jauregg accepted an appointment in a 
psychiatric clinic in 1883.  Although he had no formal training in psychiatry, which was 
still in its infancy as a discipline, he became professor of psychiatry at the University of 
Graz in 1893.  He also continued clinical research in mental health in his hospital 
practice.  Early in his career, he developed an interest in investigating the effects of 
inducing fevers in patients with psychoses, based on empirical observations from early 
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times that patients with mental illness sometimes seemed to improve when attacked by a 
fever.   
 In 1917, Wagner-Jauregg decided to  try using malaria as a form of fever therapy 
in patients with paresis.  He injected nine patients suffering from this condition with 
tertian malaria, a form of the disease which was relatively innocuous and could generally 
be cured by drug therapy with quinine.   He found that six of the cases showed significant 
remission, and in three of these cases the remission proved to be enduring.  In 1919, he 
began this experimental treatment on a large scale.  Others also began to carry out clinical 
trials with malaria therapy, which proved to be far more successful than any previous 
treatment for paresis.  In 1922, the treatment was used on the first American patient at St. 
Elizabeths Hospital in Washington, DC.  The method was soon widely accepted and 
Warner-Jauregg received the Nobel Prize in Physiology or Medicine in 1927 for his 
discovery of the therapeutic value of malaria inoculation in the treatment of paresis.14 
 Joel Braslow has argued that we cannot answer the question of whether malaria 
fever therapy actually worked with any degree of certainty.  No randomized clinical trails 
of the sort that would be accepted as evidence today were ever performed on the method.  
With the discovery of the effectiveness of penicillin against syphilis in 1943, malaria 
therapy was eventually phased out, although it remained the treatment of choice until the 
late 1940s and early 1950s, and continued to find some use even after that time.  In its 
heyday, it was certainly widely believed to be effective.  In addition, Braslow has pointed 
out that it resulted in a decided improvement in the relationship between physicians and 
paresis patients.  Whereas previously, both the patients and their doctors had viewed the 
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condition of the patients as hopeless, there was now some cause for optimism.  Braslow 
wrote: 
“The advent of malaria therapy restructured patients’ and physicians’ 
perceptions of themselves and each other.  Irrespective of whether the 
treatment worked, not only did these physicians believe that they could act 
decisively against the syphilitic spirochete, but their belief in its efficacy 
allowed them to write more sympathetically about their patients and, 
perhaps, to care for them in a less objectified and more humane way.  
Furthermore, this new technology not only allowed patients to seek 
hospitalization voluntarily but permitted even those who were there 
against their will to become active participants in their treatment.”15 
 Developments in the 1930s resulted in some modifications in the treatment of 
syphilis in its earlier stages.  As Kampmeier has pointed out, the stumbling block to 
adequate treatment with arsenicals continued to be the issue of compliance on the part of 
the patients.  A course of weekly injections for over a year was too much of a burden for 
many patients, and so often the full treatment was not carried out.  Experiments reported 
by Harold Hyman at Mount Sinai Hospital in New York in 1933 demonstrated that active 
medications could be delivered relatively safely by means of slow intravenous drip.  This 
work led Hyman’s colleague Louis Chargin to speculate that the intravenous drip 
procedure might be applied to arsenic therapy, with the possible result of curing syphilis 
in a matter of days or weeks, instead of a year or more.  However, the procedure required 
hospitalization of the patients.   
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 Chargin, Hyman and their coworkers began clinical testing of the intravenous drip 
method of Neoarsphenamine therapy for syphilis at Mount Sinai Hospital in 1933.  
Although the results were promising, the death of a patient led the team to look for a drug 
that might be less toxic and more stable.  At about this time, other investigators had 
shown that Mapharsen (arsenoxide) was much less toxic than Neoarsphenamine but 
equally as effective.  The Mount Sinai group switched to Mapharsen and continued their 
studies with good results and a substantial decrease in toxic effects in a five-day 
treatment regimen.  Large-scale clinical trials at a number of institutions confirmed these 
early results, demonstrating that at the most effective dose intravenous Mapharsen 
therapy yielded satisfactory results in 85 to 90 percent of cases of primary syphilis and 70 
percent of cases of secondary syphilis.16 
 Of course, there was also no shortage of quack doctors and patent medicines 
supposedly able to cure syphilis, as had been the case for centuries.  In nineteenth century 
America such nostrums as Swaim’s Panacea and Helmbold’s Extract of Buchu had been 
advertised as cures for syphilis.17  So-called medical or anatomy museums, generally 
aimed at men, also were often fronts for quacks who claimed to treat venereal disease and 
sexual dysfunctions.  Brooks McNamara described a typical American museum of this 
type as follows: 
“Once inside the main room, the assault on the patron’s nerves began in 
earnest.  Everywhere about him were glass cases filled with hideously 
diseased organs modeled in death-like wax or luridly painted papier-
mâché.  The lights were low, the atmosphere hushed and funereal.  Case 
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after case displayed gaping sores and hideous deformities attributed to 
syphilis, gonorrhea, or that nameless terror of the nineteenth century, the 
“secret vice,” masturbation…At this point a solicitous “floor man” would 
appear from nowhere and begin to talk to the frightened patient.  If it 
appeared that the customer was in need of medical aid – or could be 
convinced that he was – he was steered upstairs to the ‘medical institute’ 
run by an “eminent specialist” in the various secret diseases.”18 
 In the twentieth century, as regulation of the advertising and labeling of medicines 
increased in the United States and other countries, the marketers of syphilis remedies 
turned to using euphemisms for the disease in an attempt to disguise their claims.  
Everyone knew, for example, that “blood poisoning” in an advertisement meant syphilis.   
Products sold as “blood purifiers” had been used by some people as remedies for syphilis 
in the nineteenth century.  Sarsaparilla tonics, such as Ayers and Hoods, were popular in 
this regard, as this plant (as we have seen) was originally thought to be a remedy for 
syphilis.  Such products continued to be used in the 1920s and beyond.  For example, 
Compound Syrup of Sarsaparilla and Burdock with Iodide of Potassium was being sold 
as a treatment for “blood poisoning resulting from syphilis” in the 1930s.19    
 By the late nineteenth century, however, sarsaparilla had largely fallen into disuse 
for this purpose in orthodox medicine, although syrup of sarsaparilla was still being used 
as a vehicle for delivering drugs such as mercury and iodine (which were used to treat 
syphilis).  Textbooks of pharmacology of the early twentieth century generally dismiss 
the value of sarsaparilla as a remedy for syphilis.  Arthur Cushny’s popular textbook of 
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pharmacology, for example, stated that the drug “has some reputation in the treatment of 
syphilis, but there is no reason to believe that it is of any service here.”20 
 Patent medicine quacks were not hesitant to don the mantle of science to sell their 
wares.  Not long after Ehrlich discovered Salvarsan, for example, a New York charlatan 
marketed a cure for “blood poison” (syphilis) in which he used both Ehrlich’s name and 
the number 606 (a term by which Salvarsan was also known).   In the 1930s, a 
practitioner opened the “606 Medical Laboratory” in Chicago for the treatment of “men’s 
disease” – a euphemism for syphilis and gonorrhea.  The advertisement for this 
establishment could easily have given one the impression that Dr. Ehrlich himself was in 
charge.  Another twentieth century “cure” for syphilis was named Ricord’s Specific, 
drawing on the name of a famous nineteenth-century syphilologist.21  
 Dr. Sayman’s Wonder Herbs was another patent medicine of the twentieth 
century that supposedly cured syphilitic “taints.”  The remedy consisted of a mixture of 
various plant products, such as ginger, rhubarb, licorice and senna, along with sodium 
bicarbonate or sodium carbonate.  The Chief of Drug Control of the United States Food 
and Drug Administration noted in 1933 that while the medicine might be of some value 
in relieving gas in the stomach and bowel, it was worthless in the treatment of syphilis.  
Furthermore, he added: 
“Yet this concoction was recommended for syphilitic ‘taints,’ as if you 
could have just a little bit of this dread disease!  But when you have 
syphilis you have it.  It is as impossible to have a mere taint of it as it 
would be to fire off a cannon a little bit at a time.”22   
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 Quack devices were also used for the supposed diagnosis and cure of syphilis.  
Albert Abrams, “the dean of twentieth century charlatans” in the United States, built a 
series of machines which he claimed could diagnose the disease of a patient from a 
sample of dried blood, even if the patient were miles away.  In time, Abrams stated that 
the patient’s autograph would work just as well, which enabled him to diagnose syphilis 
in famous persons of the past such as Henry Wordsworth Longfellow and Edgar Allan 
Poe.  A New York “clinic” used an electrical device to treat young men who had been led 
to believe that they might be infected with syphilis.  The patient sat naked on a kind of 
toilet throne with his back against a metal plate and his scrotum suspended in a whirling 
pool of liquid.  Both the liquid and the metal plate were hooked to a battery, and the 
patient received a shock, presumably convincing him that the treatment was working.23 
 The introduction of penicillin as a therapeutic agent in the 1940s revolutionized 
the treatment of syphilis.  Alexander Fleming had accidentally discovered the anti-
bacterial properties of the Penicillium mold in 1928, and realized that a substance 
produced by the mold (which he called penicillin) might have therapeutic value as a 
topical agent against disease-causing bacteria.  It was not until the early 1940s, however, 
that researchers at Oxford University in England isolated a relatively pure form of 
Fleming’s penicillin and were able to demonstrate its therapeutic efficacy in animals and 
then in human clinical trials.  The United States government gave high priority to the 
development of penicillin on a large-scale for use in the war effort, as the drug was 
proving to be the most potent anti-bacterial substance known to date.  At first supplies 
were limited and mostly reserved for military use, but by 1944 innovations introduced in 
  15
American government, university and industry laboratories had greatly increased the 
yield and available supply of penicillin.  In April 1945, all restrictions on its distribution 
in the United States were removed.24 
 In 1943, investigators at the Mayo Clinic showed that penicillin was effective 
against gonorrhea bacilli that were resistant to the sulfa drugs, thus giving physicians 
another weapon against this venereal disease.  PHS physician John Mahoney and his 
colleagues at the Venereal Disease Research Laboratory in the PHS hospital at Staten 
Island, New York, soon confirmed these results.  But Mahoney also decided to divert a 
small amount of his limited supply of the drug from the gonorrhea research to test it 
against syphilis.  According to a coworker of Mahoney, the drug was first tried against 
the spirochetes that cause syphilis in vitro (i.e., outside of the body in a test tube or other 
apparatus) and failed to show any activity.  Fortunately, the Staten Island investigators 
proceeded to the next step in trying penicillin in vivo (i.e., in the living body) in syphilitic 
rabbits.25 
 The results of limited animal tests were so encouraging that Mahoney decided to 
move ahead to clinical experiments.  He justified this early move to testing on humans 
because penicillin appeared to be generally non-toxic and no harm would be done if the 
drug did not work and he had to return to arsenic therapy.  In 1943, it has not yet been 
recognized that penicillin could produce serious allergic side effects in some patients.26 
 In June 1943, Mahoney and his colleagues began their clinical study with four 
patients.  The results were very promising, and the Staten Island group gave a preliminary 
report of the work at a national meeting.  Although they were cautious in their report of 
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the results, especially since the study had involved only four patients, their paper created 
great excitement.  Microbiologist Gladys Hobby, who heard the presentation of the paper, 
later recalled: 
“I have a mental image of the room where I first heard Mahoney and his 
associates describe their results on the use of penicillin in the treatment of 
syphilis.  The room was crowded.  Loudspeakers and projection 
equipment were not as sophisticated then as now.  Everyone strained to 
hear what was said, and the impact was electrifying.  By then much had 
been written on penicillin, but no one had expected that an antibacterial 
agent would be active against spirochetes as well.  Hearing John Mahoney 
describe the effect of penicillin on the course of syphilitic lesions was 
overwhelming.”27 
 The story was picked up by the popular press as well.  In an article headed “New 
Magic Bullet,” Time discussed how Mahoney, in a “jam-packed session” of the meeting, 
announced that “penicillin had apparently cured four cases of early penicillin.”  Dr. 
Mahoney, according to the story, was “stunned” by the results.  The magazine also 
reported Mahoney’s cautious statement that penicillin would have to be tested in a large 
number of cases over a long period of time before it could be considered a cure for 
syphilis, but even given the limitations of the study, the results generated high hopes for 
this new drug against an old disease.  One doctor who took to the floor to comment on the 
paper at the meeting was carried away by his enthusiasm to exult: “This is probably the 
most significant paper ever presented in the medical field.” 28 At another conference a 
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month later, a PHS physician referred to the work of Mahoney and his colleagues as 
“overshadowing anything that has happened in syphilis control since the days of 
Ehrlich.”29 
 The results of the limited study at Staten Island were promising enough to lead to 
the organization of a large-scale, national clinical trial of penicillin in the treatment of 
syphilis.  Initially, eight civilian venereal disease clinics, along with one each from the 
Army, Navy and Public Health Service, participated in the study, but additional facilities 
were later included.  Not surprisingly, the Staten Island PHS hospital, where Mahoney 
and his colleagues were located, was one of the original sites for the study.  In September 
1944, Mahoney and other participants in the study published papers describing their 
results with over 1400 cases.  They were able to demonstrate that penicillin treatment led 
to the disappearance of the spirochete from open lesions, the healing of those lesions, and 
a reversal of the blood serologic response from positive to negative (presumably due to 
the elimination of spirochetes from the blood).  Further clinical trials confirmed the place 
of penicillin as the treatment of choice for syphilis.30  
 On 26 June 1944, the U. S. Army adopted penicillin as the routine treatment for 
syphilis.  Penicillin allowed military physicians to get men suffering from venereal 
disease back to being available for combat quickly.  The infected men remained 
ambulatory and began to convalesce almost immediately after treatment was begun, so 
they could be kept close to the front lines and returned to combat as soon as the therapy 
was completed.  At first, however , there was not enough penicillin available to treat all 
cases that might potentially benefit from it.  Penicillin of course had therapeutic value of 
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the treatment of war wounds and various infections diseases other than syphilis and 
gonorrhea.31  Physician-ethicist Henry Beecher called attention in a 1969 paper to the 
problem that military surgeons faced in this situation: 
“Allocation of penicillin within the Military was not without its troubles: 
When the first sizable shipment arrived at the North African Theatre of 
Operations, U.S.A., in 1943, a decision had to be made between using it 
for ‘sulfa-fast’ [sulfa-resistant] gonorrhea or for infected war wounds [its 
effectiveness against syphilis had not been fully established at the time].  
Colonel Edward D. Churchill, Chief Surgical Consultant for that Theatre, 
made the decision to use the available penicillin for those “wounded” in 
brothels.  Before indignation takes over, one must recall the military 
manpower shortage of those days.  In a week or less, those overcrowding 
the military hospitals with venereal disease could be restored to health and 
returned to the battle line.”32 
 A moral issue of a different sort was raised by those concerned about the impact 
of penicillin on sexual mores.  As it became more and more obvious that syphilis and 
gonorrhea could be cured relatively quickly and painlessly with penicillin, some feared 
that this situation would encourage sexual promiscuity and immorality.  One historian 
had cited a theologian of the period who worried that venereal disease would come to be 
regarded as strictly a medical problem, with its sociological and moral implications 
ignored.  A graduate student in social work, who completed a research project at a rapid 
treatment center in 1947, admitted in her dissertation that she could not answer the 
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question of “whether penicillin will be a help or a hindrance to the control of venereal 
disease; whether by making the treatment so short and effective patients will lose the fear 
of contracting the disease and will show more laxness in their sexual behavior.”  A 
number of public health officials suggested that the quicker and less arduous penicillin 
treatment could actually lead to an increase in venereal disease.  Johns Hopkins 
bacteriologist Thomas B. Turner, for example, gave a talk at the 1948 ASHA meeting 
entitled “Penicillin: Help or Hindrance?,” in which he discussed the successes of the drug 
against venereal disease, but also cited the loss of fear as a deterrent to exposure.  Similar 
concerns about the undermining of standards of morality had been voiced when Ehrlich’s 
Salvarsan had been introduced to treat syphilis in the early twentieth century.33 
 Concerns about the impact that penicillin might have on sexual behavior did not 
materially slow the adoption of the drug for the treatment of syphilis and gonorrhea.  Nor, 
however, did the advent of this more effective drug therapy eliminate these diseases or 
the social and moral issues surrounding them. 
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